Business Wire

VIFOR-PHARMA

26.5.2019 09:02:08 CEST | Business Wire | Press release

Share
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Nanopharmaceutics promises ground-breaking innovation in the development of medicines:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/

  • The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel
  • The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences
  • With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development

Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medical science and bring significant benefit to patients.

At present, however, researchers are only just beginning to acquire the in-depth scientific insights needed for a fundamental understanding of the development of nanomedicines, their applications and especially the regulatory requirements for their approval across Europe and worldwide. Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.

Spread over 10 years, the commitment of CHF 10 million by the Vifor Pharma Group is intended to establish the field of nanopharmacy research at the University of Basel and to support the training of corresponding experts. The newly-created professorships in Nanopharmaceutical and Regulatory Science will be based at the Department of Pharmaceutical Sciences. There are also plans to establish and develop an internationally renowned Excellence Platform for the development, authorisation and application of nanopharmaceuticals, as well as the training of experts in the field.

Vifor Pharma views its contribution as start-up funding for this Excellence Platform, which is supported and jointly endorsed by stakeholders from academia, industry and public authorities. The aim is for the platform to both focus on research and teaching, and also to seek out international partnerships, organise conferences and incorporate additional sponsors with a view to becoming a leading international centre for nanopharmacy. “In order to make rapid progress in nanopharmaceutics, we’re reliant on clear and scientifically sound parameters for authorisation and patient safety,” says Etienne Jornod, Executive Chairman of the Board of Directors at Vifor Pharma. “The field of nanopharmacy is growing quickly, and it’s important to secure a leading position in this innovative area of medicine with the help of qualified experts. That’s why we want to help ensure that Switzerland establishes a strong research foundation in this emerging area of pharmaceutical development.”

For the University of Basel, this collaboration marks an important step in the further development of its life sciences focal area. “We’re proud to be able to develop this promising field of research in collaboration with a major industrial partner,” says Professor Andrea Schenker-Wicki, President of the University of Basel. “The crucial thing here is that we’re not only developing the scientific foundations, but also training the experts who will take this knowledge with them into industry and public authorities.” It is, she says, a key step for Basel and Switzerland in terms of their ability to compete on the international stage.

Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. The Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit www.viforpharma.com .
In Switzerland Vifor Pharma has four production and research & development sites where the vast majority of medications are produced. Together with company headquarters, these sites employ over 1,300 people in Switzerland. The affiliate Vifor Pharma Switzerland is operating out of Villars-sur-Glâne in the French speaking part of the country.

The University of Basel has an international reputation of outstanding achievements in research and teaching. Founded in 1460, the University of Basel is the oldest university in Switzerland and has a history of success going back over 550 years.
As a comprehensive university offering a wide range of high-quality educational opportunities, the University of Basel attracts students from Switzerland and the entire world, offering them outstanding studying conditions as they work towards their bachelor’s, master’s or PhD degrees. Today, the University of Basel has around 13,000 students from over a hundred nations, including 2,800 PhD students. The University of Basel has seven faculties covering a wide spectrum of academic disciplines. At the same time, the university has positioned itself amidst the international competition in the form of five strategic focal areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and Energy Research and European and Global Studies. In international rankings, the University of Basel is regularly placed among the 100 top universities in the world thanks to its research achievements.
The University of Basel has deep roots in the economically powerful and culturally rich Basel region. The university also works closely with domestic and international partners to make relevant contributions to the advancement of the sciences and society. This also means that the University of Basel pays particular attention to aspects of sustainability, equal opportunity and knowledge transfer.

Contact:

Media Relations Vifor Pharma Heide Hauer Head of Corporate Communications +41 58 851 80 87 media@viforpharma.com

Media Relations University of Basel Matthias Geering Leiter Public Affairs, Kommunikation & Marketing +41 61 207 35 75 / +41 79 269 70 71 matthias.geering@unibas.ch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bolstering its Executive Team, Taktile Welcomes Engineering Powerhouse James Broadhead as CTO16.9.2026 11:00:00 CEST | Press release

Broadhead to help propel Taktile’s global growth amid surging demand for AI-powered decisioning in banking and insurance Taktile, the leader in AI transformation for financial institutions, today announced it has hired engineering veteran James Broadhead as its chief technology officer. Broadhead, who is based in Dublin, Ireland, most recently worked at Databricks and brings nearly 15 years of experience in software engineering and development, including at X (Twitter), Neon and MongoDB. At Neon, Broadhead led engineering through exponential growth of the platform driven by Agentic software development, more than tripling company revenue before its acquisition by Databricks. “Taktile is growing rapidly across global markets, and James’ leadership will be instrumental as we expand our R&D function and global footprint,” said Taktile CEO and co-founder Maik Taro Wehmeyer. “James’ extensive background and expertise in engineering will take Taktile to the next level in powering mission-cri

Vantor, UK Ministry of Defence and Industry Partners Establish Defence Intelligence Innovation Cluster – Project FAIRFAX16.9.2026 10:00:00 CEST | Press release

This new hub will bring UK government, industry and academia together at Royal Air Force station Wyton to accelerate defence & intelligence capabilities from development into operational use Vantor, the leader in unified spatial intelligence, announced today it has joined the UK Ministry of Defence and industry partners to launch the UK Defence Intelligence Innovation Cluster, a new collaboration designed to accelerate the development and deployment of next-generation defence and intelligence capabilities and strengthen the UK’s sovereign defence industrial base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916244808/en/ Vantor's Mike Buckley with RAF Wyton officials, council and industry partners at the FAIRFAX Collaboration Hub opening. The cluster is being established through Project FAIRFAX, a joint initiative between the UK Ministry of Defence, Huntingdonshire District Council, Vantor, CGI UK and MAIAR. Together, t

More than Half of Consumers are Comfortable with AI Agents Applying for Credit, Experian Research Finds16.9.2026 10:00:00 CEST | Press release

Consumers are moving beyond using AI to research financial products, with growing confidence in AI agents supporting parts of the lending journey, creating new opportunities and challenges for financial institutions. Key findings 54% of consumers are comfortable with AI agents applying for credit on their behalf. 82% trust AI to compare loans across providers. 85% believe AI agents could help compare more options than they could manually. 84% believe AI agents could help them find better prices or rates. 75% would feel more comfortable using an LLM connected to a financial institution they already trust. Consumers are ready to take the next step in their relationship with artificial intelligence (AI), according to AI in Risk: The Rise of Agentic Commerce, new research from data and technology company, Experian, conducted by Forrester Consulting. The study of 6,247 credit-active consumers across 13 EMEA and Asia Pacific markets, found that more than half (54%) of respondents are comfort

Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes16.9.2026 09:00:00 CEST | Press release

Aqara, a global leader and pioneer in IoT, today announced the release of the Spatial Multi-Sensor FP400. The FP400 is designed to bring precise, spatial intelligence to homes without sacrificing the privacy typically compromised by smart cameras. Rather than simply detecting motion or presence, the FP400 enables homes to better understand occupancy, movement, and context for more granular and personalized automations and insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916958372/en/ Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes The Spatial Multi-Sensor FP400 redefines how smart homes perceive and interact with living spaces by combining high-precision spatial sensing with AI-powered environmental understanding. Powered by a next-generation high-precision 60GHz mmWave radar, the FP400 delivers industry-leading multi-person sensing, precise

Cambridge Associates Opens Italian Office and Expands European Leadership16.9.2026 09:00:00 CEST | Press release

Global investment firm Cambridge Associates (CA) today announced the opening of a new office in Milan and the appointment of two senior hires in Europe. The move reflects the firm’s ongoing commitment to providing bespoke services to current and future institutional and family office investors across the region. Raphael Heynold has joined the Client Solutions team as Head of EMEA and APAC and will serve on the firm’s EMEA Operating Committee. Based in London, Raphael is a key member of the Global Client Solutions Leadership team, responsible for driving growth and market expansion and overseeing client engagement efforts across Europe, the Middle East, and Asia Pacific regions. Heynold brings more than 30 years of experience across client strategy, investment banking and investment management, and has worked with many sophisticated families and institutions around the world. Riccardo Pianeti has joined Cambridge Associates to lead the Italian office. He will serve as Head of the Milan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye